The US Food and Drug Administration has expanded the emergency use authorization (EUA) for the Pfizer (NYSE: PFE)-BioNTech (Nasdaq: BNTX) COVID-19 vaccine (BNT162b2) for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents through 15 years of age.
The FDA amended the EUA originally issued on December 11, 2020 for administration in individuals 16 years of age and older.
Pfizer has recently said it expects to apply for authorization for its vaccine for use in toddlers and young children in September and infants in November.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze